About Qlaris Bio
Qlaris Bio is a Healthcare company based in United States founded in 2019 by Thurein Htoo. AI-based technology is developed for treating ophthalmic diseases. Qlaris Bio has raised $58.62 million across 4 funding rounds from investors including Mayo Clinic, New Leaf Venture Partners and abrdn. Its chief executive, as recorded, is Thurein Htoo. Qlaris Bio offers products and services including QLS-111. Its focus areas include Life Sciences, Ophthalmology, Drugs and Glaucoma. Its legal entity is Qlaris Bio, Inc. Its competitors include TearClear, Aria Pharmaceuticals and Visiox Pharma; 3 of its 3 listed competitors have raised funding.
Company details
Qlaris Bio was founded in 2019 in the United States within the biotechnology sector. AI-based technology is utilized by the company to address ophthalmic diseases. A joint venture is maintained with Mayo Clinic and nference to support development efforts. The lead candidate, QLS-101, is advanced in the preclinical stage for managing intraocular pressure disturbances, a sight-threatening progressive rare disease in pediatrics.
- Headquarters United States
- Founders Thurein Htoo
- SectorsHealthcare
- Website qlaris.bio
- Social LinkedIn
- Legal Name Qlaris Bio, Inc.
- Total Equity Funding$58.62M (USD)
in 4 rounds
- Latest Funding Round$3.95M (USD), Series B
Jun 2026
- InvestorsMayo Clinic
& 4 more
Products & Services of Qlaris Bio
Qlaris Bio offers a comprehensive portfolio of products and services, including QLS-111.
Lowers intraocular pressure for glaucoma and ocular hypertension.
Funding Insights of Qlaris Bio
Qlaris Bio has successfully raised a total of $58.62M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $3.95 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $58.62M
- Total Rounds 4
- Last Round Series B — $3.95M
- First Round $25M
(Aug 2019)
- Investors Count 5
All 4 funding rounds of Qlaris Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $3.95M | Series B | – | – | – |
| Nov 2025 | $5.64M | Series B | – | – | – |
| Apr 2024 | $24.03M | Series B | – | Canaan, New Leaf Venture Partners | |
| Aug 2019 | $25M | Series A | – | Canaan, New Leaf Venture Partners |
5 investors in total: 5 institutional.
Investors in Qlaris Bio
Qlaris Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Mayo Clinic, New Leaf Venture Partners and abrdn.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Multiple sectors are invested in by abrdn's private equity fund. | 1825 | abrdn.com | Edinburgh, United Kingdom | |
Venture capital firm focused on aerospace, biopharma, consumer, and multiple sectors | correlationvc.com | San Francisco, United States | ||
General medical clinics are operated throughout the United States. | 1864 | mayoclinic.org | United States |
Investor details for Qlaris Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Qlaris Bio
21 people are tracked at Qlaris Bio (6 in leadership, 13 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Thurein Htoo | Co-Founder & CEO | Leadership |
Barbara Wirostko | Chief Medical Officer & Co-Founder | Leadership |
Barbara Wirostko MD, FARVO | Co-Founder and Chief Medical Officer | Leadership |
David Neafus | CFO | Leadership |
Lisa Brandano | Executive Director, Clinical Operations | Leadership |
Uttio Roy Chowdhury | Director, Translational Research | Leadership |
Adrienne Graves | Director | Board & advisors |
Shan Lin | Scientific Advisor | Board & advisors |
Alon Harris | Scientific Advisor | Board & advisors |
Janet Serle | Scientific Advisor | Board & advisors |
Wende Hutton | Director | Board & advisors |
Ron Hunt | Director | Board & advisors |
Andrew Danielsen | Director | Board & advisors |
Michael Fautsch | Scientific Advisor | Board & advisors |
Peter Farina | Scientific Advisor | Board & advisors |
Carol Toris | Scientific Advisor | Board & advisors |
Dan Stamer | Scientific Advisor | Board & advisors |
Alex Huang | Scientific Advisor | Board & advisors |
Vicente Anido | Strategic Advisor | Board & advisors |
Laura Rykard | Executive Assistant | Team |
1 more people are available in the full profile.
Complete people profiles for Qlaris Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Qlaris Bio
3 dated milestones of Qlaris Bio across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Qlaris Bio is founded.
- Funding First funding round of $25.0M.
- Funding Latest funding round, Series B, of $3.9M.
Competitors of Qlaris Bio
Qlaris Bio has 3 listed competitors in our database, 3 of them funded. They include TearClear, Aria Pharmaceuticals and Visiox Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tearclear.com | 2015 | Copley Township, United States | $31.98M | Filter technology for preservative-free ophthalmic drugs is developed. | ||
| ariapharmaceuticals.com | 2015 | Palo Alto, United States | $14.31M | Develops innovative drug technologies for multiple diseases. | ||
| visioxpharma.com | 2021 | Tarrytown, United States | $7M | Therapeutics for ophthalmic diseases including glaucoma are developed. |
Detailed competitors of Qlaris Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Qlaris Bio
The website of Qlaris Bio (qlaris.bio) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 24.4% vs previous month
Top companies in Ophthalmology
3 companies that operate in the same segment as Qlaris Bio (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Qlaris Bio
Complete news archive for Qlaris Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qlaris Bio
Qlaris Bio was founded in 2019.
Qlaris Bio is headquartered in United States.
Thurein Htoo is the CEO of Qlaris Bio, as recorded in our data. They have also founded this company.
Qlaris Bio is a funded company, having raised a total of $58.62M across 4 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Aug 2019.
Qlaris Bio was founded in 2019 in the United States within the biotechnology sector. AI-based technology is utilized by the company to address ophthalmic diseases. A joint venture is maintained with Mayo Clinic and nference to support development efforts. The lead candidate, QLS-101, is advanced in the preclinical stage for managing intraocular pressure disturbances, a sight-threatening progressive rare disease in pediatrics.
Qlaris Bio's top competitors include Visiox Pharma, TearClear and Aria Pharmaceuticals.
Qlaris Bio offers QLS-111.
Qlaris Bio has 5 investors. Key investors include Mayo Clinic, New Leaf Venture Partners, abrdn, Canaan, and Correlation Ventures.
Qlaris Bio operates through Qlaris Bio, Inc..